2
Clinical Trials associated with CD19-TriCAR SILK cell therapy (Timmune Biotech)Adoptive Immunotherapy for Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell
This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Children CD19+ Leukemia Non-Hodgkin lymphoma treatment.
Adoptive Immunotherapy for Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell
This is a single arm, open-label, early phase Ⅰ study, to determine the safety and efficacy of CD19-TriCAR-T and CD19-TriCAR-SILK cell therapy in Non-Hodgkin lymphoma treatment.
100 Clinical Results associated with CD19-TriCAR SILK cell therapy (Timmune Biotech)
100 Translational Medicine associated with CD19-TriCAR SILK cell therapy (Timmune Biotech)
100 Patents (Medical) associated with CD19-TriCAR SILK cell therapy (Timmune Biotech)
100 Deals associated with CD19-TriCAR SILK cell therapy (Timmune Biotech)